.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH02_Romidepsin.Romidepsin

Information

Romidepsin is a cyclic peptide histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is approved by regulatory agencies such as the FDA for these indications.

Pharmacokinetics

Pharmacokinetic parameters are reported in adult patients with advanced cancers, administered intravenous infusion over 4 hours. Parameters derived from population PK modeling.

References

1. Peer, CJ, et al., & Figg, WD (2018). A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer chemotherapy and pharmacology 82(3) 565–570. DOI:10.1007/s00280-018-3631-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29951694

2. Gerber, DE, et al., & Schiller, JH (2015). Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 90(3) 534–541. DOI:10.1016/j.lungcan.2015.10.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474959

3. Stadler, WM, et al., & Thompson, JA (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical genitourinary cancer 5(1) 57–60. DOI:10.3816/CGC.2006.n.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16859580

Revisions

• 06/2025 initial generated model